Chronic Plaque PsoriasisPhase 3NCT02581345
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 study testing M923 and Humira in people with Chronic Plaque Psoriasis and Psoriasis, run by Momenta Pharmaceuticals, Inc. at 90 sites in 9 countries.
Trial summary
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Plaque Psoriasis, Psoriasis
- What is being tested?
- M923 and Humira
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 572 participants
- Where
- 90 sitesin 9 countries
- Study dates
- Sep 2015to 4 Apr 2017
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must be able to understand and communicate with the investigator and comply with the requirements of the study
- Chronic plaque-type psoriasis diagnosed for at least 6 months before screening
- Stable plaque psoriasis
- History of receipt of or candidate for therapy.
- Moderate to severe psoriasis at screening and baseline
- Must be willing and able to self-administer SC injections or have a caregiver available to administer injections
- Male participants of childbearing potential must employ a highly effective contraceptive measure
- Female participants must have a negative pregnancy test; are not planning to become pregnant; and must not be lactating. Female participants must also agree to employ a highly effective contraceptive measure.
Who cannot join
- Forms of psoriasis other than chronic plaque-type
- Drug-induced psoriasis.
- Other skin conditions which would interfere with assessment of psoriasis
- Medical conditions other than psoriasis for which systemic corticosteroids were used in the last year prior to screening
- Other inflammatory conditions other than psoriasis or psoriatic arthritis
- Prior use of systemic tumor necrosis factor (TNF) inhibitors, or 2 or more non-TNF biologic therapies
Show all 21Show fewer
- Ongoing use of prohibited psoriasis treatments
- Ongoing use of other non-psoriasis prohibited treatments
- All other prior non-psoriasis concomitant treatments must be on a stable dose for at least 4 weeks
- Laboratory abnormalities at screening deemed clinically significant by the investigator
- Any condition or illness which in the opinion of the investigator or sponsor poses an unacceptable safety risk
- History of latex allergy
- History of or current signs or symptoms or diagnosis of a demyelinating disorder
- History of or current Class III or IV New York Heart Association congestive heart failure
- Signs, symptoms, or diagnosis of lymphoproliferative disorders, lymphoma, leukemia, myeloproliferative disorders, or multiple myeloma
- Current malignancy or history of any malignancy except adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ; no more than 3 lifetime basal cell and squamous cell carcinomas permitted
- Chronic infections, recurrent infections; recent infection to be evaluated
- History of or presence of human immunodeficiency virus (HIV), or Hepatitis B (HBV) or C virus (HCV)
- History of active tuberculosis (TB) or untreated or inadequately treated latent TB.
- Exposure to an investigational product ≤30 days prior to enrollment or participation in another clinical study during the course of this study
- Participant is a family member or employee of the investigator or site staff or study team
Trial locations and contacts
90 sites in 9 countries.
90 sites in 9 countries
United States24 sites
Radiant Clinical Research
Anderson, South Carolina, 29621
Wallace Medical Group, Inc.
Beverly Hills, California, 90211
Tufts Medical Center; Inc.
Boston, Massachusetts, 02111
Radiant Research; Inc.
Cincinnati, Ohio, 45249
Radiant Research, Inc.
Columbus, Ohio, 43212
Horizons Clinical Research Center, LLC
Denver, Colorado, 80220
Encino Research Center
Encino, California, 91436
Palmetto Clinical Trial Services, LLC
Fountain Inn, South Carolina, 29644
Radiant Research, Inc.
Greer, South Carolina, 29650
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46256
eStudySite
La Mesa, California, 91942
eStudySite
Las Vegas, Nevada, 89109
Bioclinical Research Alliance; Inc
Miami, Florida, 33155
Sanitas Reasearch, LLC
Miami, Florida, 33155
Renstar Medical Research
Ocala, Florida, 34471
eStudySite
Oceanside, California, 92056
Compass Research, LLC
Orlando, Florida, 32806
Radiant Research; Inc.
Overland Park, Kansas, 66210
Austin Institute for Clinical Research, LLC
Pflugerville, Texas, 78660
National Clinical Research-Richmond, Inc
Richmond, Virginia, 23294
Clinical Trials of Texas; Inc.
San Antonio, Texas, 78229
eStudySite
San Diego, California, 92120
Shahram Jacobs MD, INC
Sherman Oaks, California, 91403
Bay State Clinical Trials, Inc
Watertown, Massachusetts, 02472
Poland19 sites
Poradnia Kardiologiczna Jaroslaw Jurowiecki
Gdansk, 80-286
Medica Pro Familia Sp. z o. o. S.K.A. Oddzial w Gdyni
Gdynia, 81-338
NZOZ POLIMEDICA FILIA KIELCE (Niepubliczny Zaklad Opieki Zdrowotnej POLIMEDICA)
Kielce, 25-364
Medica Pro Familia Sp. z o.o. SK.A.
Krakow, 30-002
Grazyna Pulka Specjalistyczny Osrodek ALL-MED
Krakow, 31-023
Centrum Terapii Wspolczesnej _J.M. Jasnorzewska Sp. Komandytowo-Akcyjna
Lodz, 90-242
Centrum Medyczne Szpital Swietej Rodziny
Lodz, 90-302
NZOZ ALL-MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie
Lodz, 94-048
KO-MED Centra Kliniczne Lublin II
Lublin, 20-362
Medicome sp.zoo
Oświęcim, 32-600
Centrum Badan Klinicznych S.C.
Poznan, 60-773
Ai Centrum Medyczne
Poznan, 61-113
KO-MED Centra Kliniczne Pulawy
Puławy, 24-100
Centrum Medyczne Medyk
Rzeszów, 35-055
NZOZ Nasz Lekarz
Torun, 87-100
Medica Pro Familia Sp. z o.o. S.K.A.
Warsaw, Masovian Voivodeship, 01-868
MTZ Clinical Research Sp z o.o.
Warsaw, 02-106
KO-MED Centra Kliniczne Zamosc
Zamość, 22-400
Nzoz Polimedica
Zgierz, 95-100
Canada10 sites
Mediprobe Research Inc
London, Ontario, N5X 2P1
Recherche GCP Research
Montreal, Quebec, H1M 1B1
Dr. David Gratton Dermatologue Inc.
Montreal, Quebec, H3H 1V4
SKDS Research Inc
Newmarket, Ontario, L3Y 5G8
North Bay Dermatology Centre
North Bay, Ontario, P1B 3Z7
Office of Dr. Michael Robern
Ottawa, Ontario, K2G 6E2
The Centre for Dermatology
Richmond Hill, Ontario, K2G 6E2
London Road Diagnostic Clinic and Medical Centre
Sarnia, Ontario, N7T 4X3
Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
Ste-Foy, Quebec, G1V 4X7
K Papp Clinical Research Inc
Waterloo, Ontario, N2J 1C4
Czechia8 sites
CCBR Czech Brno, s.r.o
Brno, 60200
Dermatologie - MUDr. HELENA KORANDOVA s.r.o.
Olomouc, Povel, 779 00
CCBR Czech a.s
Pardubice, 530 02
CCBR Czech Prague s.r.o
Prague, Czech Republic, 13000
Clintrial s.r.o
Prague, 100 00
Fakultni nemocnice Kralovske Vinohrady
Prague, 100 34
MUDr. Jaroslav Dragon - Kozni ordinace
Ústí nad Labem, 400 10
Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem Dermatovenerologicke oddeleni
Ústí nad Labem, 40113
Estonia7 sites
Parnu Hospital
Pärnu, 80010
Vahlberg & Pild OU
Tallinn, 10134
East Tallinn Central Hospital
Tallinn, 11312
North Estonia Medical Centre Foundation
Tallinn, 13419
Medicum AS
Tallinn, 13619
Kliiniliste Uuringute Keskus (Clinical Research Centre)
Tartu, 50106
Tartu University Hospital; Dermatology Clinic
Tartu, 50417
Germany6 sites
Klinische Forschunq Schwerin GmbH
Dorf Mecklenburg, Vorpommern, 19055
Praxis fuer Dermatologie und Venerologie
Dresden, 01097
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, 01307
Klinikum der Johann Wolfgang Goethe-Universitaet
Frankfurt am Main, 60590
Clinical Research Hamburg
Hamburg, 22143
Universitaetsklinikum Schleswig Holstein
Schleswig, Holstein, 23538
Latvia6 sites
Riga 1 st Hospital
Riga, 1001
Derma Clinic Riga Ltd
Riga, LV-1003
Health Centre 4
Riga, LV-1003
J. Kisis Ltd
Riga, LV-1003
Health Centre 4
Riga, LV-1013
Ventspils Outpatient Clinic
Ventspils, LV-3601
Bulgaria5 sites
Medical Centre Asklepii, OOD
Dupnitsa, 2600
DCC Sveti Georgi EOOD
Haskovo, 6300
UMHAT Dr.Georgi Stranski, EAD
Pleven, 5800
DCC Sv. Georgi, EOOD
Plovdiv, 4000
Department of Dermatology and Venereology, Faculty of Medicine, UMHAT Alexandrovska
Sofia, 1431
Slovakia5 sites
Derma therapy spol. s.r.o.
Bratislava, 851 01
Pedi-Derma s.r.o.
Košice, Košice Region, 04011
Nemocnica Kosice-Saca, a.s., 1.sukromna nemocnica
Košice, 04015
Dema-beauty, s.r.o
Nitra, 949 01
Sanare S.r.o
Svidník, 089 01
About this study
Official title: A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
- Conditions
- Chronic Plaque Psoriasis, Psoriasis
- Being tested
- M923, Humira
- Keywords
- Moderate to severe chronic plaque psoriasis, Psoriasis
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
M923Biological
Also called Adalimumab
Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
HumiraBiological
Also called Adalimumab
Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
| Study group | Role | What they receive |
|---|---|---|
| M923 | Experimental | Participants assigned to receive M923 Receives: Biological: M923 |
| Humira | Active comparator | Participants assigned to receive Humira Receives: Biological: Humira |
| M923 and Humira | Other | Participants assigned to receive M923 and Humira Receives: Biological: M923; Biological: Humira |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% in the Week 16 PASI score compared to the score at Baseline.
Measured: Baseline; Week 16
Secondary outcomes (35)
Percentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 16
The sPGA response rate was defined as the percentage of participants who had achieved a clear or almost clear response on the 6-point sPGA scale. The sPGA was the physician's determination of the participant's psoriasis lesions overall at a given time point. Overall lesions were categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis was assessed at a given time point on a 6-point scale on which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe.
Measured: Week 16
Number of Participants Achieving PASI 50 Response at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.
Measured: Baseline; Week 16
Number of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.
Measured: Baseline; Week 52
Number of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% compared to Baseline.
Measured: Baseline; Week 52
Number of Participants Achieving PASI 90 Response at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.
Measured: Baseline; Week 16
Number of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.
Measured: Baseline; Week 52
Absolute PASI Score at Baseline
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
Measured: Baseline
Absolute PASI Score at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
Measured: Week 16
Absolute PASI Score at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
Measured: Week 52
Percent Change From Baseline in PASI Score at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) * 100.
Measured: Baseline; Week 16
Percent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) * 100.
Measured: Baseline; Week 52
Health-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
Measured: Baseline
Health-Related Quality of Life During Treatment: DLQI Score at Week 16
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
Measured: Week 16
Health-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit)
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
Measured: Week 48
Health-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine". Baseline was defined as the last scheduled observation prior to dosing, typically Day 1, predose.
Measured: Baseline
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 16
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".
Measured: Week 16
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit)
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".
Measured: Week 48
Number of Participants With Clinically Meaningful Changes in Vital Signs
Vital signs included body temperature, respiratory rate, pulse rate, systolic and diastolic blood pressure, and weight. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Measured: Up to Week 52
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Baseline
Laboratory results included hematology [Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis [Specific Gravity] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Measured: Baseline
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 16
Laboratory results included hematology [Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis [Specific Gravity] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Measured: Week 16
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 48 (Completion/Termination Visit)
Laboratory results included hematology [Red Blood Cell Count, Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes absolute, Monocytes, Eosinophils absolute, and Eosinophils], chemistry (Aspartate transaminase, Alanine transaminase, Alkaline Phosphatase, Gamma glutamyl transferase, Total bilirubin, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Sodium, Potassium, Chloride, Urea, Creatinine, Albumin, Phosphate, Glucose, and Uric acid) and urinalysis [pH and Specific Gravity] parameters. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Measured: Week 48
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
Measured: Baseline
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 16
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
Measured: Week 16
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit)
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
Measured: Week 48
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs are adverse events that occurred during or after study drug administration. For more details on adverse events please refer the safety section.
Measured: Up to Week 52
Pharmacokinetics: Serum Concentrations by Treatment
Serum samples were collected at Baseline (Week 0, perdose), approximately 1 week (peak) after IP administration (Weeks 8 and 16), and 2 weeks after dose administration as a trough sample collected prior to the next dose administration (Weeks 17, 21, 25, 29, 37, 41).
Measured: Baseline (Week 0), Week 8, 16, 17, 21, 25, 29, 37, and 41
Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) at Baseline
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Measured: Baseline (Week 0)
Immunogenicity: Number of Participants With ADA at Week 16
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Measured: Week 16
Immunogenicity: Number of Participants With ADA at Week 25
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Measured: Week 25
Immunogenicity: Number of Participants With ADA at Week 52 (Completion/Termination Visit)
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Measured: Week 52
Immunogenicity: Number of Participants With ADA and nADA by Titer at Baseline
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Measured: Baseline (Week 0)
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 16
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Measured: Week 16
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 25
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Measured: Week 25
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 52 (Completion/Termination Visit)
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Measured: Week 52
Median Time to Seroconversion
Time to seroconversion (in days) was defined as the time to the observation of the first confirmed positive ADA response. Participants with confirmed positive ADA response at baseline (Week 0 predose) were excluded.
Measured: Up to Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2015 (estimated)
- Study startSep 2015
- Primary completion4 Apr 2017
- Study completion4 Apr 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Chronic Plaque PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 572 participants (actual)
Sponsor and investigators
- Lead sponsor
- Momenta Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- John Caminis, MD, Study director, Shire
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02581345
- Sponsor's protocol ID
- 911401
- Status last verified
- Oct 2018
- First submitted
- 19 Oct 2015
- Last updated
- 17 Oct 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
- ClinicalTrials.gov ID
- NCT02581345
- Acronym / sponsor ID
- 911401
- Conditions
- Chronic Plaque Psoriasis, Psoriasis
- Keywords
- Moderate to severe chronic plaque psoriasis, Psoriasis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 572 participants (actual)
- Lead sponsor
- Momenta Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- Sep 2015
- Primary completion
- 4 Apr 2017 (actual)
- Study completion
- 4 Apr 2017 (actual)
- First posted
- 21 Oct 2015 (estimated)
- Results
- Posted 12 Sep 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| M923 | Experimental | Biological: M923Participants assigned to receive M923 |
| Humira | Active comparator | Biological: HumiraParticipants assigned to receive Humira |
| M923 and Humira | Other | Biological: M923, Biological: HumiraParticipants assigned to receive M923 and Humira |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Must be able to understand and communicate with the investigator and comply with the requirements of the study
- Chronic plaque-type psoriasis diagnosed for at least 6 months before screening
- Stable plaque psoriasis
- History of receipt of or candidate for therapy.
- Moderate to severe psoriasis at screening and baseline
Key exclusion criteria (21 listed)
- Forms of psoriasis other than chronic plaque-type
- Drug-induced psoriasis.
- Other skin conditions which would interfere with assessment of psoriasis
- Medical conditions other than psoriasis for which systemic corticosteroids were used in the last year prior to screening
- Other inflammatory conditions other than psoriasis or psoriatic arthritis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| M923Also: AdalimumabRecombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α) | Biological | M923, M923 and Humira |
| HumiraAlso: AdalimumabRecombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α) | Biological | Humira, M923 and Humira |
Primary outcome
Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16
Time frame: Baseline; Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% in the Week 16 PASI score compared to the score at Baseline.
35 secondary outcomes
Percentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 16
Time frame: Week 16
Number of Participants Achieving PASI 50 Response at Week 16
Time frame: Baseline; Week 16
Number of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit)
Time frame: Baseline; Week 52
Number of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit)
Time frame: Baseline; Week 52
Number of Participants Achieving PASI 90 Response at Week 16
Time frame: Baseline; Week 16
Number of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit)
Time frame: Baseline; Week 52
Absolute PASI Score at Baseline
Time frame: Baseline
Absolute PASI Score at Week 16
Time frame: Week 16
Absolute PASI Score at Week 52 (Follow-Up Visit)
Time frame: Week 52
Percent Change From Baseline in PASI Score at Week 16
Time frame: Baseline; Week 16
Percent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit)
Time frame: Baseline; Week 52
Health-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline
Time frame: Baseline
Health-Related Quality of Life During Treatment: DLQI Score at Week 16
Time frame: Week 16
Health-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit)
Time frame: Week 48
Health-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline
Time frame: Baseline
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 16
Time frame: Week 16
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit)
Time frame: Week 48
Number of Participants With Clinically Meaningful Changes in Vital Signs
Time frame: Up to Week 52
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Baseline
Time frame: Baseline
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 16
Time frame: Week 16
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 48 (Completion/Termination Visit)
Time frame: Week 48
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline
Time frame: Baseline
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 16
Time frame: Week 16
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit)
Time frame: Week 48
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Week 52
Pharmacokinetics: Serum Concentrations by Treatment
Time frame: Baseline (Week 0), Week 8, 16, 17, 21, 25, 29, 37, and 41
Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) at Baseline
Time frame: Baseline (Week 0)
Immunogenicity: Number of Participants With ADA at Week 16
Time frame: Week 16
Immunogenicity: Number of Participants With ADA at Week 25
Time frame: Week 25
Immunogenicity: Number of Participants With ADA at Week 52 (Completion/Termination Visit)
Time frame: Week 52
Immunogenicity: Number of Participants With ADA and nADA by Titer at Baseline
Time frame: Baseline (Week 0)
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 16
Time frame: Week 16
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 25
Time frame: Week 25
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 52 (Completion/Termination Visit)
Time frame: Week 52
Median Time to Seroconversion
Time frame: Up to Week 52
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Oct 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Chronic Plaque Psoriasis
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Psoriasis
RecruitingObservational study
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Acne, Atopic Dermatitis
RecruitingPhase 4
An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis
Chronic Plaque Psoriasis, Nail Psoriasis
RecruitingPhase 2
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
Psoriasis
RecruitingObservational study
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
Chronic Plaque-type Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John Caminis, MD study director
Shire
90 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing M923 and Humira in people with Chronic Plaque Psoriasis and Psoriasis, run by Momenta Pharmaceuticals, Inc. at 90 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 90 sites in United States, Poland, Canada, Czechia, Estonia and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Sep 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16 (time frame: Baseline; Week 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Oct 2018.